More than 150 people took part as Providence Cancer Center participated in Vice President Biden’s Cancer Moonshot Summit. The goal is to make a decade worth of advances toward a cure in five years, from increasing access to treatment and improving care to freeing trapped data and unleashing new breakthroughs.
We mourn the passing of Earle M. Chiles, 83, a long-time champion and supporter of providing exceptional health care for Providence patients in Oregon.
Excited by the promise and power of immunotherapy research, Providence Cancer Center supporters raised nearly $1 million in the month of May, with most of that coming at the 2016 Creating Hope through Innovation Dinner May 25.
Just a year into her career as a Providence Cancer Center radiation oncologist and scientist, Kristina Young, M.D., Ph.D., has been recognized as...
Providence researchers have identified an immunotherapy approach that synergizes with radiation so well it not only eliminated the tumor in most preclinical models with pancreatic cancer, it found and destroyed distant, cancer cells – which could have grown into lethal metastatic tumors.
Providence Cancer Center researchers might have identified how to determine if a patient with advanced melanoma will likely respond to a certain immunotherapy treatment.
A breakthrough drug for treating the most common type of lung cancer was just approved by the Food and Drug Administration ahead of schedule following two successful clinical trials, including one that involved patients at Providence Cancer Center in Portland.
Cancer patients in Oregon, Washington and three other Western states will receive improved access to care and clinical trials as a result of a new $6.6 million grant from the National Cancer Institute’s Community Oncology Research Program, or NCORP.